Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration
Primary Purpose
Alcohol Use Disorder
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Low frequency repetitive transcranial magnetic stimulation (rTMS)
Sham
Sponsored by
About this trial
This is an interventional treatment trial for Alcohol Use Disorder
Eligibility Criteria
Inclusion Criteria:
- Overtly healthy men and women aged 21 - 35
- Able to give informed consent
- Able to understand/complete questionnaires and procedures in English
- Willing and able to adhere to the study schedule
- At least 2 binge drinking events (at least 4 or 5 drinks on a drinking day for women and men respectively over the last 5 weeks, unless determined by study physicians that drinking history meets study objectives
- Have venous access sufficient to allow blood sampling
Exclusion Criteria:
- Pregnant or breast-feeding
- Desire to be treated for any substance use disorder or court ordered to not drink alcohol
- Medical disorders or other conditions, such as lifetime history of a seizure, including history of Electroconvulsive therapy (ECT) but excluding febrile seizures and those induced by substance withdrawal, that may influence study outcome or subject safety
- First degree relative with idiopathic epilepsy or other seizure disorder
- Diagnostic and Statistical Manual (DSM) 5 Disorders (non-AUD) or current/history of neurological disease of cerebral origin, or head injury with > 20 min loss of consciousness, if determined by the study physicians to affect subject safety or data integrity
- Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine if determined by the study physicians to adversely affect subject safety or data integrity
- Medications (past 30 days) that could influence subject data/subject safety (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by study physicians
- Positive BrAC reading at beginning of any study session
- Actively suicidal (for example, any suicide attempts within the past 3 months or any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the study physicians
- Any condition for which the study physicians determine it is unsafe or not prudent to enroll a subject
Sites / Locations
- Neural Systems LabRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Low frequency repetitive transcranial magnetic stimulation (rTMS)
Sham rTMS Stimulation
Arm Description
Low frequency repetitive transcranial magnetic stimulation (rTMS)
Sham rTMS Stimulation
Outcomes
Primary Outcome Measures
Time to raise breath alcohol concentration (BrAC)
The amount of time subjects take to self-administer enough alcohol to raise their breath alcohol concentration (BrAC) to 80 mg/dL
Secondary Outcome Measures
Drinking patterns
Drinking patterns as measured by Time Line Follow Back (TLFB) during the 4-week follow-up period. The Timeline Follow-back (TLFB) is modified to assess for one-month recall of alcohol, tobacco, drug, and cannabis use. Using a calendar, subjects provide retrospective estimates of their daily drinking over a specified time period.
Full Information
NCT ID
NCT04971681
First Posted
July 12, 2021
Last Updated
August 10, 2023
Sponsor
Indiana University
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
1. Study Identification
Unique Protocol Identification Number
NCT04971681
Brief Title
Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration
Official Title
Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 8, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This will be a single site randomized, 2-session, within-subject cross-over design pilot study. 20 enrolled (of 30 consented) subjects reporting varying levels of binge and high intensity drinking, defined as at least 2 episodes of drinking 4 (for women) or 5 (for men) drinks on an occasion over the last 5 weeks, (unless determined by PI that drinking history meets study objectives), will be enrolled. Subjects will be randomized to undergo one session of repetitive transcranial magnetic stimulation (rTMS) or sham immediately followed by the investigators rate control intravenous (IV) alcohol self-administration (ASA) paradigm. Subjects will then return 7-14 days later and undergo the same sequence of events with the opposite intervention (i.e. rTMS or sham) from session 1.
Detailed Description
This pilot study intends to address the critical unmet need to develop novel treatments for alcohol use disorder (AUD), such as repetitive transcranial magnetic stimulation (rTMS), that directly impact drinking behavior. Binge drinking and high intensity drinking, or consumption meeting at least binge criteria, is a high-risk alcohol self-administration (ASA) pattern associated with the binge-intoxication stage of AUD and the rewarding effects of alcohol. The investigators propose to quantify the impact of medial prefrontal cortex (mPFC) rTMS on ASA using the investigators novel "rate-control" paradigm. The rate control paradigm allows subjects to determine how quickly their breath alcohol concentration (BrAC) will change (increase, decrease, or stay the same) over the next 3-5 minute epoch, at the end of which brief computer-assisted assay of craving for alcohol and subjective response attributed to alcohol's effect on stimulation, sedation, liking and well-being in a manner comparable to the Brief Biphasic Alcohol Effects Scale (BAES). Each assay requires less than 20 seconds to complete and will be administered during the last ~0.5 minutes of alcohol delivery but before selection of the next rate of exposure. The ensemble provides detailed self-administered time course of alcohol exposure and corresponding time-stamped series of quantified perceptions for analysis. This approach has demonstrated sensitivity in associating self-reported high intensity drinking and the time until a binge alcohol exposure of 80 milligrams per decilitre (mg/dL).
The investigators premise is that clinically impactful neuromodulation should change ASA. Coupling rTMS to a laboratory-assessed ASA paradigm could document causal changes in drinking behavior attributable to modulation of specific neural circuits. The goal of this project is to generate preliminary data supporting the investigators central hypothesis - rTMS targeting to the mPFC, a primary cortical input to the frontal-striatal reward (FSR) circuit, will decrease the rate of alcohol self-administration.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Use Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Low frequency repetitive transcranial magnetic stimulation (rTMS)
Arm Type
Experimental
Arm Description
Low frequency repetitive transcranial magnetic stimulation (rTMS)
Arm Title
Sham rTMS Stimulation
Arm Type
Sham Comparator
Arm Description
Sham rTMS Stimulation
Intervention Type
Device
Intervention Name(s)
Low frequency repetitive transcranial magnetic stimulation (rTMS)
Intervention Description
Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
Intervention Type
Device
Intervention Name(s)
Sham
Intervention Description
The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
Primary Outcome Measure Information:
Title
Time to raise breath alcohol concentration (BrAC)
Description
The amount of time subjects take to self-administer enough alcohol to raise their breath alcohol concentration (BrAC) to 80 mg/dL
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Drinking patterns
Description
Drinking patterns as measured by Time Line Follow Back (TLFB) during the 4-week follow-up period. The Timeline Follow-back (TLFB) is modified to assess for one-month recall of alcohol, tobacco, drug, and cannabis use. Using a calendar, subjects provide retrospective estimates of their daily drinking over a specified time period.
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Overtly healthy men and women aged 21 - 35
Able to give informed consent
Able to understand/complete questionnaires and procedures in English
Willing and able to adhere to the study schedule
At least 2 binge drinking events (at least 4 or 5 drinks on a drinking day for women and men respectively over the last 5 weeks, unless determined by study physicians that drinking history meets study objectives
Have venous access sufficient to allow blood sampling
Exclusion Criteria:
Pregnant or breast-feeding
Desire to be treated for any substance use disorder or court ordered to not drink alcohol
Medical disorders or other conditions, such as lifetime history of a seizure, including history of Electroconvulsive therapy (ECT) but excluding febrile seizures and those induced by substance withdrawal, that may influence study outcome or subject safety
First degree relative with idiopathic epilepsy or other seizure disorder
Diagnostic and Statistical Manual (DSM) 5 Disorders (non-AUD) or current/history of neurological disease of cerebral origin, or head injury with > 20 min loss of consciousness, if determined by the study physicians to affect subject safety or data integrity
Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine if determined by the study physicians to adversely affect subject safety or data integrity
Medications (past 30 days) that could influence subject data/subject safety (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by study physicians
Positive BrAC reading at beginning of any study session
Actively suicidal (for example, any suicide attempts within the past 3 months or any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the study physicians
Any condition for which the study physicians determine it is unsafe or not prudent to enroll a subject
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ann E Kosobud, PHD
Phone
317-274-0087
Email
akosobud@iupui.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Martin H Plawecki, MD
Phone
317-948-6550
Email
mplaweck@iu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Conroy, MD
Organizational Affiliation
Indiana University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neural Systems Lab
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NSL Recruiter
Phone
317-948-6551
Email
erptest@iupui.edu
First Name & Middle Initial & Last Name & Degree
Ann E Kosobud, PHD
Phone
317 274-0087
Email
akosobud@iupui.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration
We'll reach out to this number within 24 hrs